7000+ rare genetic diseases affect 400 million people worldwide. 95% lack therapy, 50% are children. We seek solutions within the vast redundancy already present in the human genome.
Today's approved stem cell therapies for genetic disorders are toxic, unscalable, slow, and expensive, all rooted in ex-vivo approaches. We're developing an in-vivo alternative, a single, off-the-shelf injection that cures patients without chemotherapy or cell transplantation. Accessible to all patients worldwide and independent of their genetic mutations, no patient will be left behind.
Ten startups have been selected for the 2026 Venture Leaders Biotech program, which will take them to Boston from May 31st to June 5th as part of the Swiss National Startup Team. During their roadshow, Immitra Bio will connect with international investors and industry leaders, acquiring expertise to help scale their ventures internationally.
Immitra Bio has received Venture Kick support to advance an in-vivo gene editing platform for blood disorders. The approach enables gene correction directly in the body, without chemotherapy, making curative therapies faster, safer, and more scalable.
Forbes 30Under30, the annual premier list that presents influential personalities in Switzerland, Germany, and Austria who positively impact business and society. Selected from startups offering solutions in various sectors and prominent figures supporting the ecosystem.
Our biological blueprint is layered with echoes and redundancies, an untapped pool of information waiting to be exploited.
We are building at the frontier of biology and engineering, turning fundamental discoveries into new therapeutic possibilities.
Driving vision and strategy at Immitra Bio, translating a bold scientific thesis into a scalable company.
Experienced gene editing expert with deep pharmaceutical industry background.
Key Opinion Leader in cutting-edge CRISPR-Cas9 technologies, Genome Biology Professor at ETH Zurich.
Cell and Molecular Biologist, experienced with characterization of proteins and their function, ETH Zurich alumni.
Cell and Molecular Biologist, experienced in primary and stem cell biology as well as mass spec proteomics, ETH Zurich alumni.
Supported by a growing network of leading investors and research partners.
We are building scalable in-vivo genomic medicine for blood disorders. Whether you are an investor, partner, scientist, or operator, reach out directly.
Immitra Bio GmbH
Route de la Galaise 34
1228 Plan-les-Ouates, Geneva, Switzerland
At Immitra Bio, we value your privacy. This Privacy Policy explains how we handle any personal information when you visit our website.
No Data Collection: We do not collect any personal information from our website visitors. We do not require you to provide any personal details to access or use the website. No Third-Party Services: We do not use any third-party services, such as analytics tools, advertising, or other embedded content, that might collect or track your data. Cookies: Our website may use cookies for basic functionality, such as ensuring the proper operation of the website. These cookies do not collect any personal information. Changes to this Policy: We may update this Privacy Policy from time to time. Any changes will be posted on this page, and the updated policy will be effective as of the date it is posted.If you have any questions about this Privacy Policy, feel free to contact us at info@immitrabio.com.
